PMID- 35381015
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20220510
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 4
DP  - 2022
TI  - Role of urinary H2O2, 8-iso-PGF2alpha, and serum oxLDL/beta2GP1 complex in the diabetic 
      kidney disease.
PG  - e0263113
LID - 10.1371/journal.pone.0263113 [doi]
LID - e0263113
AB  - Oxidant species is reported as a major determinant in the pathophysiology of 
      diabetic kidney disease. However, reactive oxygen species (ROS) formation in the 
      initial phase and progressing phase of diabetic kidney disease remains unclear. 
      Therefore, we conducted this study to find out what ROS and their modified 
      product are associated with eGFR in type 2 diabetes mellitus (T2DM) patients. A 
      cross-sectional study was performed on 227 T2DM patients. The study subjects were 
      divided into three groups based on their eGFR stage (Group 1, eGFR > 89 
      ml/min/1.73 m2; Group 2, eGFR = 60-89 ml/min/1.73 m2; and Group 3, eGFR < 60 
      ml/min/1.73 m2). Enzyme-linked immunosorbent assay (ELISA) was used to measure 
      serum oxLDL/beta2GPI complex and urinary 8-iso-PGF2alpha, while ferrous ion oxidation 
      xylenol orange method 1 (FOX-1) was used to measure urinary hydrogen peroxide 
      (H2O2). H2O2 significantly decreased across the groups, whereas OxLDL/beta2GPI 
      complex increased, but not significant, and there was no trend for 8-iso-PGF2alpha. 
      Consistently, in the total study population, only H2O2 showed correlation with 
      eGFR (r = 0.161, p = 0.015). Multiple linear regression analysis showed that 
      significant factors for increased eGFR were H2O2, diastolic blood pressure, and 
      female. Whereas increased systolic blood pressure and age were significant 
      factors affecting the decrease of eGFR. We also found that urinary H2O2 had 
      correlation with serum oxLDL/beta2GPI complex in total population. This finding 
      could lead to further research on urinary H2O2 for early detection and research 
      on novel therapies of diabetic kidney disease.
FAU - Sauriasari, Rani
AU  - Sauriasari R
AUID- ORCID: 0000-0001-7861-4369
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Zulfa, Afina Irsyania
AU  - Zulfa AI
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Sekar, Andisyah Putri
AU  - Sekar AP
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Azmi, Nuriza Ulul
AU  - Azmi NU
AD  - Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
FAU - Tan, Xian Wen
AU  - Tan XW
AD  - Department of Cell Chemistry, Okayama University Graduate School of Medicine, 
      Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
FAU - Matsuura, Eiji
AU  - Matsuura E
AD  - Department of Cell Chemistry, Okayama University Graduate School of Medicine, 
      Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
AD  - Collaborative Research Center (OMIC), Okayama University Graduate School of 
      Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
AD  - Neutron Therapy Research Center, Okayama University, Okayama, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220405
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (oxidized low density lipoprotein)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - B7IN85G1HY (Dinoprost)
RN  - BBX060AN9V (Hydrogen Peroxide)
SB  - IM
MH  - Biomarkers
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Nephropathies
MH  - Dinoprost/analogs & derivatives
MH  - Female
MH  - Humans
MH  - Hydrogen Peroxide
MH  - Lipoproteins, LDL
MH  - Reactive Oxygen Species
PMC - PMC8982868
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/04/06 06:00
MHDA- 2022/04/15 06:00
PMCR- 2022/04/05
CRDT- 2022/04/05 17:10
PHST- 2021/06/01 00:00 [received]
PHST- 2022/01/13 00:00 [accepted]
PHST- 2022/04/05 17:10 [entrez]
PHST- 2022/04/06 06:00 [pubmed]
PHST- 2022/04/15 06:00 [medline]
PHST- 2022/04/05 00:00 [pmc-release]
AID - PONE-D-21-16934 [pii]
AID - 10.1371/journal.pone.0263113 [doi]
PST - epublish
SO  - PLoS One. 2022 Apr 5;17(4):e0263113. doi: 10.1371/journal.pone.0263113. 
      eCollection 2022.